Meropenem + Nacubactam (OP0595/ RG6080)

Class: Drug combination: beta-lactam (carbapenem) + beta-lactamase inhibitor (diazabicyclooctane)

Spectrum of activity:	Gram-negative
Details of activity:	Bacterial infections
Combined with other compounds:	yes
Institute where first reported:	Meiji Seika Pharma Co. Ltd./Fedora Pharmaceuticals Inc. (Roche licensee)
Highest developmental phase:	Phase 1
Development status:	Active

Chemical structure(s):
Nacubactam
Canonical SMILES:	C1C[C@@H](C(=O)NOCCN)N2C[C@@H]1N(C2=O)OS(=O)(=O)O
Isomeric SMILES:	C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)NOCCN
InChI:	InChI=1S/C9H16N4O7S/c10-3-4-19-11-8(14)7-2-1-6-5-12(7)9(15)13(6)20-21(16,17)18/h6-7H,1-5,10H2,(H,11,14)(H,16,17,18)/t6-,7+/m1/s1
InChI Key:	RSBPYSTVZQAADE-RQJHMYQMSA-N
Meropenem
Canonical SMILES:	C[C@@H]1[C@@H]2[C@@H]([C@@H](C)O)C(=O)N2C(=C1S[C@H]3C[C@@H](C(=O)N(C)C)NC3)C(=O)O
Isomeric SMILES:	C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O
InChI:	InChI=1S/C17H25N3O5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4/h7-12,18,21H,5-6H2,1-4H3,(H,24,25)/t7-,8-,9+,10+,11-,12-/m1/s1
InChI Key:	DMJNNHOOLUXYBV-PQTSNVLCSA-N

External links:
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/441130
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/73386748
Guide to Pharmacology:	nacubactam
Main Source:	https://www.meiji.com/global/
Citations:	https://idsa.confex.com/idsa/2018/webprogram/Paper71491.html https://www.ncbi.nlm.nih.gov/pubmed/30012751 https://www.ncbi.nlm.nih.gov/pubmed/30590470